3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
86
Radiotherapy
71
Paclitaxel
50
Fluorouracil
38
Carboplatin
36
Drug Therapy
32
Neoadjuvant Therapy
23
toripalimab
19
tislelizumab
18
pembrolizumab
17
camrelizumab
17
Irinotecan
17
Esophagectomy
17
Surgical Procedures, Operative
16
Radiation
16
Docetaxel
16
sintilimab
15
Oxaliplatin
14
130-nm albumin-bound paclitaxel
14
nimotuzumab
11
TP protocol
11
S 1 (combination)
11
Radiotherapy, Intensity-Modulated
11
Cetuximab
11
Capecitabine
11
Albumin-Bound Paclitaxel
10
apatinib
9
Leucovorin
9
Immune Checkpoint Inhibitors
8
nedaplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Squamous Cell Carcinoma
×
monalizumab
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn